Candidate: Tollovir™ (NLC-V-01)
Type: 3CL protease inhibitor being developed through a joint venture between Todos Medical and NLC Pharma.
2021 Status: Todos Medical said April 19 that it began a Phase II trial of Tollovir™ (NLC-V-01) in hospitalized COVID-19 patients. The randomized, double blind, placebo-controlled trial, being conducted at Shaare Zedek Medical Center in Jerusalem, will evaluate the safety and efficacy of Tollovir for the treatment of COVID-19 in hospitalized patients. The trial’s primary endpoints are time to discharge from the hospital, and time to clinical improvement based upon the National Early Warning Score 2 (NEWS2) in Israel.
On April 1, a team of U.S. researchers published a preclinical study in Nature Communications identifying three structurally diverse compounds—compound 4, GC376, and MAC-5576—as inhibitors of the SARS-CoV-2 3CL protease. The compounds “may aid in the future development of novel inhibitors to combat this virus,” the investigators wrote.
COVID-19: 300 Candidates and Counting
To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: